| Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial PJ Bröckelmann, H Goergen, U Keller, J Meissner, R Ordemann, ... JAMA oncology 6 (6), 872-880, 2020 | 144 | 2020 |
| Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials S Sasse, PJ Bröckelmann, H Goergen, A Plütschow, H Müller, S Kreissl, ... Journal of Clinical Oncology 35 (18), 1999-2007, 2017 | 140 | 2017 |
| PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial P Borchmann, A Plütschow, C Kobe, R Greil, J Meissner, MS Topp, ... The Lancet Oncology 22 (2), 223-234, 2021 | 129 | 2021 |
| The emerging role of immune checkpoint inhibition in malignant lymphoma I Hude, S Sasse, A Engert, PJ Bröckelmann Haematologica 102 (1), 30, 2017 | 124 | 2017 |
| Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials B Böll, H Goergen, K Behringer, PJ Bröckelmann, F Hitz, A Kerkhoff, ... Blood, The Journal of the American Society of Hematology 127 (18), 2189-2192, 2016 | 112 | 2016 |
| Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma PJ Bröckelmann, H Müller, O Casasnovas, M Hutchings, B von Tresckow, ... Annals of Oncology 28 (6), 1352-1358, 2017 | 90 | 2017 |
| Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 S Reinke, PJ Bröckelmann, I Iaccarino, M Garcia-Marquez, S Borchmann, ... Blood, The Journal of the American Society of Hematology 136 (25), 2851-2863, 2020 | 59 | 2020 |
| Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom PJ Bröckelmann, S McMullen, JB Wilson, K Mueller, S Goring, ... British journal of haematology 184 (2), 202-214, 2019 | 54 | 2019 |
| Prognostic factors in Hodgkin lymphoma PJ Broeckelmann, MK Angelopoulou, TP Vassilakopoulos Seminars in Hematology 53 (3), 155-164, 2016 | 51 | 2016 |
| Hematological immune related adverse events after treatment with immune checkpoint inhibitors R Kramer, A Zaremba, A Moreira, S Ugurel, DB Johnson, JC Hassel, ... European Journal of Cancer 147, 170-181, 2021 | 49 | 2021 |
| Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials B von Tresckow, S Kreissl, H Goergen, PJ Bröckelmann, T Pabst, ... The Lancet Haematology 5 (10), e462-e473, 2018 | 49 | 2018 |
| Balancing risk and benefit in early-stage classical Hodgkin lymphoma PJ Bröckelmann, S Sasse, A Engert Blood, The Journal of the American Society of Hematology 131 (15), 1666-1678, 2018 | 47 | 2018 |
| Hodgkin lymphoma in adults: diagnosis, treatment, and follow-up PJ Bröckelmann, DA Eichenauer, T Jakob, M Follmann, A Engert, ... Deutsches Ärzteblatt International 115 (31-32), 535, 2018 | 46 | 2018 |
| Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin study group HD7 to HD12 trials PJ Bröckelmann, H Goergen, C Kohnhorst, B Von Tresckow, A Moccia, ... Journal of Clinical Oncology 35 (13), 1444-1450, 2017 | 43 | 2017 |
| Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition. I Hude, S Sasse, PJ Bröckelmann, B von Tresckow, J Momotow, A Engert, ... British Journal of Haematology 181 (6), 2018 | 36 | 2018 |
| Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL … PJ Bröckelmann, I Bühnen, J Meissner, K Trautmann-Grill, P Herhaus, ... Journal of Clinical Oncology 41 (6), 1193-1199, 2023 | 35 | 2023 |
| Pretreatment vitamin D deficiency is associated with impaired progression-free and overall survival in Hodgkin lymphoma S Borchmann, M Cirillo, H Goergen, L Meder, S Sasse, S Kreissl, ... Journal of Clinical Oncology 37 (36), 3528-3537, 2019 | 35 | 2019 |
| Pandemic 2009 influenza A (H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients JJ Vehreschild, PJ Bröckelmann, C Bangard, J Verheyen, M Vehreschild, ... Epidemiology & Infection 140 (10), 1848-1852, 2012 | 35 | 2012 |
| In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection S Sobesky, L Mammadova, M Cirillo, EEE Drees, J Mattlener, H Dörr, ... Med 2 (10), 1171-1193. e11, 2021 | 33 | 2021 |
| Early response to first-line anti–PD-1 treatment in hodgkin lymphoma: A PET-based analysis from the prospective, randomized phase II NIVAHL trial CA Voltin, J Mettler, L van Heek, H Goergen, H Müller, C Baues, U Keller, ... Clinical Cancer Research 27 (2), 402-407, 2021 | 30 | 2021 |
